Syndax Announces Pricing of $200 Million Public Offering of Common Stock
WALTHAM, Mass., Dec. 14, 2023 /PRNewswire/ — Syndax Pharmaceuticals, Inc. (“Syndax” or the “Company”) (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing…
